CTLA4 and lung carcinoma: Summarizing these initial results, our study describes the relevance of PD‐1, CTLA‐4, and NKG2D immunocheckpoints on immune cells subsets and, even greater, their value as biomarkers associated to complete pathological response to neoadjuvant chemoimmunotherapy in lung cancer patients.